Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
0.0356
-0.1404 (-79.77%)
At close: Mar 27, 2026, 4:00 PM EDT
0.0369
+0.0013 (3.65%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Iterum Therapeutics Revenue
Iterum Therapeutics had revenue of $390.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $390.00K.
Revenue (ttm)
$390.00K
Revenue Growth
n/a
P/S Ratio
4.82
Revenue / Employee
$43,333
Employees
9
Market Cap
1.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionITRM News
- 1 day ago - Iterum files wind-up petition due to limited cash, inability to raise equity - Reuters
- 1 day ago - Iterum Therapeutics Announces Filing of Winding Up Petition - GlobeNewsWire
- 6 weeks ago - Iterum Therapeutics Provides Business Update - GlobeNewsWire
- 4 months ago - Iterum Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 - GlobeNewsWire
- 5 months ago - Iterum Therapeutics to Present Data at IDWeek 2025 - GlobeNewsWire
- 7 months ago - Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - GlobeNewsWire
- 8 months ago - Iterum Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire